Analyst Price Targets — VKTX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 28, 2026 11:41 am | — | Lake Street | $89.00 | $31.66 | TheFly | Viking Therapeutics initiated with a Buy at Lake Street |
| May 27, 2026 10:08 am | Gregory Renza | Truist Financial | $83.00 | $30.80 | StreetInsider | Truist Securities Assumes Viking Therapeutic (VKTX) at Buy |
| April 30, 2026 1:11 pm | — | Morgan Stanley | $95.00 | $30.39 | TheFly | Viking Therapeutics price target lowered to $95 from $99 at Morgan Stanley |
| April 30, 2026 11:54 am | Steve Seedhouse | Cantor Fitzgerald | $100.00 | $31.33 | TheFly | Viking Therapeutics price target lowered to $100 from $105 at Cantor Fitzgerald |
| March 12, 2026 4:48 pm | Roger Song | Jefferies | $101.00 | $35.47 | StreetInsider | Jefferies Reiterates Buy Rating on Viking Therapeutic (VKTX): "VKTX is in an execution mode this year" |
| February 12, 2026 1:16 pm | Michael Ulz | Morgan Stanley | $99.00 | $31.07 | TheFly | Viking Therapeutics price target lowered to $99 from $102 at Morgan Stanley |
| November 12, 2025 11:43 am | Edward Nash | Canaccord Genuity | $107.00 | $40.60 | StreetInsider | Viking Therapeutic (VKTX) PT Raised to $107 at Canaccord Genuity |
| October 29, 2025 9:33 am | Edward Nash | Canaccord Genuity | $106.00 | $34.93 | TheFly | Canaccord starts Viking Therapeutics with Buy on obesity potential |
| October 23, 2025 12:05 pm | — | Morgan Stanley | $102.00 | $31.42 | TheFly | Viking Therapeutics price target raised to $102 from $98 at Morgan Stanley |
| October 23, 2025 11:16 am | — | Cantor Fitzgerald | $105.00 | $31.42 | TheFly | Viking Therapeutics offered 'transformative' Q3 update, says Cantor Fitzgerald |
Latest News for VKTX
SAN DIEGO, Sept. 2, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that it will participate at the Annual Cantor Global Health Conference, the Morgan Stanley 24th Annual Global Healthcare Conference, and the Bernstein 3rd Annual Healthcare Forum in…
Canada Pension Plan Investment Board bought a new position in shares of Viking Therapeutics, Inc. (NASDAQ: VKTX) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 26,500 shares of the biotechnology company's stock, valued at approximately $1,034,000. Other institutional investors
Bank of New York Mellon Corp acquired a new position in shares of Viking Therapeutics, Inc. (NASDAQ: VKTX) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 407,840 shares of the biotechnology company's stock, valued at approximately $15,910,000. Bank of New
Shares of Viking Therapeutics, Inc. (NASDAQ: VKTX - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the twelve analysts that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, eight have given a buy recommendation and one has
The stock still presents a compelling case for investors, provided the clinical trial data can back up the early promise in its lead drug candidate.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for VKTX.
U.S. House Trading
No House trades found for VKTX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.